Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab
Catherine J. Hwang, Erin E. Nichols, Brian Chon, Julian D. Perry
Abstract
Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.
Topics & Concepts
Optic neuropathyMedicineThyroidGraves' diseaseThyroid diseaseEye diseaseGraves' ophthalmopathySurgeryOptic nerveOphthalmologyInternal medicineOphthalmology and Eye DisordersPituitary Gland Disorders and TreatmentsGlaucoma and retinal disorders